Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)

Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program CSU is a chronic skin ...
The Maravi Post

Italy rejects 2026 World Cup slot as Iran row explodes

ROME-(MaraviPost)-Italy has firmly rejected a controversial proposal to replace Iran national football team at the 2026 FIFA ...
The Maravi Post

Israeli airstrike kills Lebanese journalist Amal Khalil

AL-TAYRI-(MaraviPost)-A Lebanese journalist has been killed in an Israeli airstrike in southern Lebanon while covering the ...

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous ...
Supply Chain Management Review

What It Really Means: Operational excellence

Operational excellence implies more than meeting internally defined goals. It reflects not just the setting of stretch ...